| Unique ID issued by UMIN | UMIN000013660 |
|---|---|
| Receipt number | R000015862 |
| Scientific Title | Evaluation of the diagnosis accuracy and eradication protocol of Helicobacter pylori gastritis in CKD 5 hemodialysis patients |
| Date of disclosure of the study information | 2014/04/08 |
| Last modified on | 2020/04/29 12:21:16 |
Evaluation of the diagnosis accuracy and eradication protocol of Helicobacter pylori gastritis in CKD 5 hemodialysis patients
The diagnosis and eradication of Helicobacter pylori in CKD
Evaluation of the diagnosis accuracy and eradication protocol of Helicobacter pylori gastritis in CKD 5 hemodialysis patients
The diagnosis and eradication of Helicobacter pylori in CKD
| Japan |
Hemodialysis patients with Helicobacter pylori gastritis
| Gastroenterology | Nephrology |
Others
NO
In dialysis patients with a Helicobacter pylori gastritis, to evaluate the efficacy and accuracy of different diagnosis methods for Helicobacter pylori gastritis and the possibility of dose reduction on eradication therapy of the disease.
Safety,Efficacy
Exploratory
Pragmatic
Phase IV
Eradication rate for Helicobacter pyroli
Sensitivity and specificity of anti-Helicobacter pylori Antibody-IgG, Dry weight during dialysis, blood pressure, body weight, chest X-ray CTR, hemoglobin, dose of ESA, serum iron, UIBC (not to TIBC), ferritin, CRP.
Observational
| 20 | years-old | <= |
| Not applicable |
Male and Female
1) Patients of CKD stage G4 ~ 5 (eGFR <= 30, including hemodialysis patients
2) Patients were revealed as chronic gastritis by upper gastrointestinal fiberscopy
2) Outpatients with relatively stable renal function.
3) Patients who can take medication orally.
4) Patients who can receive blood tests.
5) Patients that agreed to diagnosis and treatment of H.pyroli.
6) Men and women aged over 20 years old
1) Patients with a history of hypersensitivity for amoxicillin, clarithromycin, proton pump inhibitors, or metronidazole.
2) Of the patients with CKD, the patient being predicted for initiating dialysis within six months.
3) Patients complicated with acute inflammatory disease or active infection.
4) Patients with active malignant tumor.
5) Patients who suspected of being pregnant or pregnancy.
6) Patients did not make a consent for test and/or treatment of H. pyroli gastritis.
7) Patients was determined to be difficult to continue the eradication therapy by serious adverse events.
8) Patients offer discontinuation of the study.
9) Attending physician deems the patients as unsuitable of the study.
30
| 1st name | |
| Middle name | |
| Last name | Ichiei NARITA |
Niigata University Graduate School of Medical & Dental Sciences
Division of Clinical Nephrology & Rheumatology
1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 951-8510 Japan
+81-25-227-2200
naritai@med.niigata-u.ac.jp
| 1st name | |
| Middle name | |
| Last name | Yuichi SAKAMAKI |
Niigata University Graduate School of Medical & Dental Sciences
Division of Clinical Nephrology & Rheumatology
1-757 Asahimachi-Dori, Chuo-Ku, Niigata, 951-8510 Japan
+81-25-227-2200
ysakamaki-dm@umin.net
Division of Clinical Nephrology & Rheumatology, Niigata University Graduate School of Medical & Dental Sciences
none
Self funding
NO
新潟大学医歯学総合病院(新潟県)
財団法人 小千谷総合病院(新潟県)
| 2014 | Year | 04 | Month | 08 | Day |
Unpublished
Completed
| 2014 | Year | 01 | Month | 01 | Day |
| 2014 | Year | 04 | Month | 01 | Day |
| 2014 | Year | 04 | Month | 08 | Day |
| 2014 | Year | 12 | Month | 31 | Day |
Relevance of eradication rate and dose reduction of antibacterial drugs in Helocobacter pylori eradication therapy.
Retrospective study.
| 2014 | Year | 04 | Month | 07 | Day |
| 2020 | Year | 04 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015862